Bonner J, Carhart JM, Stetson B. Psychological predictors of self-reported physical activity initiation in type 2 diabetes patients following diabetes self-management education. Annals of Behavioral Medicine, 2011, 41 (S243). Paper session.
Carhart JM, Stetson B. Hypoglycemia Experience and Barrier Associations with Physical Activity in Type 1 Diabetes. 2011. Rapid Communication Presentation at the 32nd Annual Meeting of the Society of the Behavioral Medicine, Washington DC. Poster presentation.
Winner JG, Allen JA, Carhart JM, Dechairo B. Psychiatric pharmacogenomic decision support: meta analysis of prospective studies shows improved antidepressant efficacy and predicted outcomes. CINP: Pharmacogenomics and Personalized Medicine in Psychiatry. April 2013. Poster presentation.
Hall-Flavin D, Furmaga K, Allen JA, Carhart JM, Winner JG, Altar CA. Translational pharmacogenomics: physician use and satisfaction with an integrated, multi-gene psychiatric pharmacogenomic test and interpretive report. American Psychiatric Association. May 2013. Poster presentation.
Hall-Flavin D, Allen JA, Carhart JM, Winner JG, Snyder K, Drews M, Proctor B, Eisterhold LL, Geske JR, Mrazek DA. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenetics and Genomics, 2013. (http://www.ncbi.nlm.nih.gov/pubmed/24018772)
WInner JG, Carhart JM, Allen JA, Altar CA. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discovery Medicine, 2013.(http://www.ncbi.nlm.nih.gov/pubmed/24229738)
Altar CA, Carhart JM, Allen JD, Hall-Flavin DK, DeChairo BM, Winner JG. Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. The Pharmacogenomics Journal, 2015. (http://www.ncbi.nlm.nih.gov/pubmed/25686762) CV ms
Winner JG, Carhart JM, Altar CA, Goldfarb S Lavezzari G, Parsons KK, Marshak AG, Garavaglia A, Dechario BM. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res Opin, 2015. (http://www.ncbi.nlm.nih.gov/pubmed/26086890) ms
Altar CA, Carhart JM, Allen JD, Hall-Flavin D, Winner JG, Dechairo BM. Clinical Utility of combinatorial pharmacogenomics-guided antidepressant therapy: evidence from three clinical studies. Mol Neuropsychiat, 2015. (https://www.karger.com/Article/FullText/430915) CU ms